Meeting
2022 ASCO Annual Meeting
Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.
Authors
Xiao-Li Wei
Department of Medical Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China
Xiao-Li Wei , Fenghua Wang , Xiaochen Zhang , Nong Xu , Jie Gao , Xuan Pu , Zhoushuai Qin , Miao Guo , Bin Zhang , Renbin Zhao , Sean Sean Zhang , Rui-hua Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04685226
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3106)
DOI
10.1200/JCO.2022.40.16_suppl.3106
Abstract #
3106
Poster Bd #
98
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.
First Author: Nong Xu
Poster
2020 Gastrointestinal Cancers Symposium
Safety, pharmacokinetics, and efficacy of RC48-ADC in a phase I study in patients with HER2-overexpression advanced solid cancer.
First Author: Jifang Gong
Poster
2019 ASCO Annual Meeting
First-time in-human study of VMD-928, an allosteric and irreversible TrkA selective inhibitor, in patients with solid tumors or lymphoma.
First Author: Vincent Chung
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang